Gland Pharma Ltd is primarily a contract manufacturer of injectables. The company originated as by PVN Raju in 1978 to manufacture and market Heparin injection for the domestic market and provide contract manufacturing services for other pharmaceutical companies. In 2000, the company signed its first contract manufacturing agreement to set up a regulated markets R&D facility at Dundigal, Hyderabad. It continued its growth with the entry into the US market with Ketorolac PFS in 2007. In 2014, the company started manufacturing lines for ophthalmic and automated bags at the Dundigal facility. It received approval for Enoxaparin injection for the US market in 2018. The company won the Hyderabad Customs Top Exporters Award in 2017-18. The company was listed on NSE and BSE in 2020 after a successful IPO. Gland Pharma purchased assets of Vitane Biologics, a Hyderabad-based biopharmaceutical company, in 2021. It finished the acquisition of Cenexi, a French pharmaceutical company, in 2023.

Business Segments

• India Business:The company adopted direct marketing for its B2C operations in the Indian market. The Domestic Marketing Business Unit delivers a vast array of niche products across several therapeutic segments, including Anti-Infectives, Haematinics, etc.
• Therapeutic Coverage:The organization deals in therapeutic products in various categories, such as anti-malarials, gynaecological, hormones, etc. It is among the largest and fastest-growing global pure-play injectable companies.

Subsidiary

As of March 31, 2023, Gland Pharma International Pte. Ltd is the only wholly-owned subsidiary incorporated in Singapore. It gained complete control of Cenexi and cis now looking at the overall gained complete control of business.

Key Personnel

Srinivas Sadu, Managing Director & Chief Executive Officer Mr Srinivas Sadu has been the Managing Director and CEO since 2019. He joined Gland Pharma as the general manager – of exports in 2000 and rose up the ranks to become Chief Operating Officer in 2011. He has a rich experience of over 23 years in business development, manufacturing operations, supply chain management and strategic planning. He holds a master's degree in Industrial Pharmacy from Long Island University, New York; an MBA from the University of Maryland, Baltimore; and a postgraduate certification in Finance and Management from the London School of Business and Finance.

Corporate Action

The company has no history of stock splits, bonus issues and corporate action.

Management Outlook

• The strategic priorities of the organization revolve around geographical expansion. Therefore, China will continue to remain its key core priority as a couple of its products filed there are in the advanced stages of regulatory review. The organization also looks to expand its presence in the RoW markets, especially in South Africa and Kazakhstan.
• The organization has been investing in new manufacturing lines for technologies involving microspheres and combi-vials to support its complex development portfolio.